Online citations, reference lists, and bibliographies.
← Back to Search

A Preliminary Study Of Ritonavir, An Inhibitor Of HIV-1 Protease, To Treat HIV-1 Infection.

M. Markowitz, M. Saag, W. Powderly, A. Hurley, A. Hsu, J. Valdes, D. Henry, F. Sattler, A. La Marca, J. Leonard
Published 1995 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
BACKGROUND Ritonavir is a potent inhibitor in vitro of human immunodeficiency virus type 1 (HIV-1) protease, which is needed for virions to mature and become infective. We assessed the safety and efficacy of ritonavir in patients with HIV-1 infection. METHODS We administered ritonavir orally to 62 patients in one of four dosages during a 12-week trial containing a 4-week randomized, placebo-controlled, double-blinded phase followed by an 8-week dose-blinded phase. We assessed the response with serial measurements of plasma viremia and serial CD4 cell counts. RESULTS Fifty-two patients completed the 12-week trial. Diarrhea and nausea were the most common side effects, and reversible elevations in serum triglyceride and gamma-glutamyltransferase levels were the most frequent laboratory abnormalities. Ritonavir had a rapid antiviral effect, with a mean maximal reduction in the number of copies of HIV-1 RNA per milliliter of plasma that ranged from 0.86 to 1.18 log in the four dosage groups. After 12 weeks of treatment, the antiviral effect was partially maintained, with a mean reduction in plasma viremia of 0.5 log. When we used a more sensitive assay for HIV-1 RNA in a subgroup of 20 patients, we found that plasma viremia decreased by a mean of 1.7 log. This antiviral effect was partly sustained at week 12, with a mean reduction of approximately 1.1 log. The patients' CD4 cell counts rose during treatment with ritonavir (median increase, 74 and 83 cells per cubic millimeter at weeks 4 and 12, respectively). CONCLUSIONS The protease inhibitor ritonavir is well tolerated and has a potent antiviral effect, as shown by substantial decreases in plasma viremia and significant elevations in CD4 cell counts. Expanded clinical trials of ritonavir are warranted.
This paper references
10.1073/PNAS.85.13.4686
Active human immunodeficiency virus protease is required for viral infectivity.
N. Kohl (1988)
10.1126/SCIENCE.2548279
Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease.
A. Wlodawer (1989)
10.1038/337615A0
Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1
M. Navia (1989)
10.1126/SCIENCE.2183354
Rational design of peptide-based HIV proteinase inhibitors.
N. Roberts (1990)
10.1126/SCIENCE.2200122
Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.
J. Erickson (1990)
10.1128/AAC.35.11.2209
Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease.
D. Kempf (1991)
10.1056/NEJM199306103282307
Therapy for human immunodeficiency virus infection.
M. Hirsch (1993)
10.1126/SCIENCE.8278812
Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors.
P. Lam (1994)
10.1073/PNAS.91.9.4096
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.
J. Vacca (1994)
10.1038/373123A0
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
D. Ho (1995)
10.1097/00042560-199504120-00003
Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay.
C. Pachl (1995)
10.1038/373117A0
Viral dynamics in human immunodeficiency virus type 1 infection
X. Wei (1995)
10.1128/JVI.69.2.701-706.1995
Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor
M. Markowitz (1995)
10.1089/AID.1995.11.353
Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma.
Y. Cao (1995)
10.1073/PNAS.92.7.2484
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.
D. Kempf (1995)
10.1097/00042560-199504000-00006
Early and prolonged decrease of viremia in HIV-1-infected patients treated with didanosine.
S. Yerly (1995)



This paper is referenced by
10.1007/s00261-021-03205-6
Imaging of Kaposi sarcoma
Dhivya Addula (2021)
10.1007/s11095-021-03048-2
Molecular, Solid-State and Surface Structures of the Conformational Polymorphic Forms of Ritonavir in Relation to their Physicochemical Properties
Chang Wang (2021)
10.3390/biomedicines9030313
Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
Ruxandra Marin (2021)
10.1007/S42451-021-00335-5
S1-Leitlinie: Diagnostik und Therapie HIV-1-assoziierter neurologischer Erkrankungen
K. Hahn (2021)
10.1016/j.clml.2020.05.017
Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma.
N. Nathwani (2020)
10.20944/preprints202004.0240.v1
Potential Phytochemicals as Efficient Protease Inhibitors of 2019-nCoV
Anuj Ranjan (2020)
10.1038/s41392-020-00213-8
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhe Zhang (2020)
10.3390/md18070338
Bioactive Indolyl Diketopiperazines from the Marine Derived Endophytic Aspergillus versicolor DY180635
Yi-li Ding (2020)
10.1007/s11481-019-09886-7
CNS Neurotoxicity of Antiretrovirals
Tyler A Lanman (2019)
10.1186/s12981-019-0236-0
Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)
L. Taramasso (2019)
10.1007/978-3-030-13377-1_6
Disorders of the Pancreas
Mary Snayd (2019)
10.1097/QAD.0000000000001796
Global HIV neurology: a comprehensive review
K. Thakur (2019)
10.1097/MPA.0000000000001190
Hypertriglyceridemia-Associated Drug-Induced Acute Pancreatitis
Mohamed A. Elkhouly (2019)
10.1093/cid/ciy324
A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa
S. Ba (2018)
10.1007/978-3-319-91092-5_18
Modelling the Adaptive Immune Response in HIV Infection with Three Saturated Rates and Therapy
K. Allali (2018)
10.1097/QAI.0000000000001747
Propelling the Pediatric HIV Therapeutic Agenda With Science, Innovation, and Collaboration
E. Abrams (2018)
10.3389/fimmu.2018.00643
Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine
B. Kim (2018)
10.1016/j.watres.2018.08.017
Environmental fate and ecotoxicological effects of antiretrovirals: A current global status and future perspectives.
S. Ncube (2018)
10.1208/s12249-018-1060-x
Generation of a Weakly Acidic Amorphous Solid Dispersion of the Weak Base Ritonavir with Equivalent In Vitro and In Vivo Performance to Norvir Tablet
Daniel J Ellenberger (2018)
10.1007/s41061-018-0184-5
Analysis of US FDA-Approved Drugs Containing Sulfur Atoms
Kevin A. Scott (2018)
10.1016/B978-0-444-63849-6.00019-0
Global developments in HIV neurology.
E. Wright (2018)
10.1007/978-1-4939-0694-9_28
HIV protease inhibitor resistance
A. Wensing (2017)
10.20959/wjpps20178-9760
A REVIEW ON DRUG INDUCED HEPATOTOXICITY AND ITS MANAGEMENT BY HERBAL DRUGS
G. N. Singh (2017)
10.1051/MMNP/201712501
On HIV Model with Adaptive Immune Response, Two Saturated Rates and Therapy
K. Allali (2017)
10.16966/2470-3206.120
HIF-1α Inhibitors for the Treatment of Posterior Segment Ocular Diseases
Kelly Sj (2017)
10.22028/D291-26681
Improving and validating data-driven genotypic interpretation systems for the selection of antiretroviral therapies
A. Pironti (2016)
10.1093/jac/dkv429
Backbones versus core agents in initial ART regimens: one game, two players.
J. M. Llibre (2016)
10.2147/HIV.S70836
Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy
N. von Hentig (2016)
10.13023/ETD.2016.040
THE ROLE OF PXR AND IKKβ SIGNALING IN CARDIOMETABOLIC DISEASE
Robert N. Helsley (2016)
Characterization of inducible reservoirs of HIV-1
Anthony R Cillo (2016)
10.1080/13543784.2016.1212837
Investigational protease inhibitors as antiretroviral therapies
Narasimha M. Midde (2016)
Efecto de las concentraciones de ritonavir en la farmacocinética de atazanavir: aplicación de técnicas de modelado y simulación farmacocinético poblacional /
J. A. Gómez (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar